Bempedoic acid (formerly ESP-55016; ETC-1002; ESP55016; ETC1002; Nexletol; Bempedoate) is an ATP-citrate lyase (ACL) inhibitor as well as an activator of hepatic AMP-activated protein kinase (AMPK). It has been approved as an orally bioavailable, once-daily LDL-C lowering drug for the treatment of hypercholesterolemia. It was designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. Bempedoic acid is absorbed rapidly in the small intestine and enters the liver through cell surface receptors different from those transporters that selectively take up statins. Bempedoic acid is a regulator of lipid and carbohydrate metabolism.